COL-ECMO2022

RYCHLÍČKOVÁ, Jitka, Pavel SUK, Vendula KUBÍČKOVÁ a Karel URBÁNEK. COL-ECMO2022. In CZECRIN Výroční vědecká konference 2023. 2023. ISBN 978-80-280-0336-4.

Základní údaje

• Originální název: COL-ECMO2022
• Název česky: COL-ECMO2022
• Název anglicky: COL-ECMO2022
• Autoři: RYCHLÍČKOVÁ, Jitka (203 Česká republika, garant, domácí), Pavel SUK (203 Česká republika, domácí), Vendula KUBÍČKOVÁ (203 Česká republika) a Karel URBÁNEK (203 Česká republika).
• Vydání: CZECRIN Výroční vědecká konference 2023, 2023.

Další údaje

• Originální jazyk: čeština
• Typ výsledku: Konferenční abstrakt
• Obor: 30104 Pharmacology and pharmacy
• Stát vydavatele: Česká republika
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Kód RIV: RIV/00216224:14110/23:00131098
• Organizační jednotka: Lékařská fakulta
• ISBN: 978-80-280-0336-4
• Klíčová slova anglicky: COL-ECMO2022
• Štítky: rivok
• Příznaky: Mezinárodní význam

Anotace

The COL-ECMO2022 study is a prospective, non-randomized, single-center, phase IV clinical trial designed to assess the influence of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics of colistin. Colistin is administered as colistin methanesulfonate (CMS), which is spontaneously hydrolyzed to the active form. Colistin is also a drug with a narrow therapeutic window; the limiting factors are mainly nephrotoxicity and neurotoxicity, both dependent on plasma concentrations. Thirdly, there are limited data on the influence of ECMO on colistin and CMS pharmacokinetics. Up to 30 patients treated with colistin will be included in the study and assigned to one of two arms, depending on the presence/absence of ECMO. All study participants will receive standard CMS dose intravenously. The plasma concentrations of colistin and CMS taken at defined intervals will be assessed by high-performance liquid chromatography-mass spectrometry. Patients will participate in the clinical trial for a maximum of three monitored dosing intervals. A population pharmacokinetic model will be developed to assess the influence of ECMO on pharmacokinetics. The study has been approved by the Ethics Committee of St. Anne's University Hospital Brno (Number 10ML/2022-AM). EudraCT Number of the study is 2022-000291-19, registered on June 21, 2022. The study was registered at the Clinical Trials register https://clinicaltrials.gov/ct2/show/NCT05542446 on September 15, 2022. Acknowledgment: Activities related to the development of a method for the determination of colistin in plasma were covered by a grant Verification of colistin adsorption on the ECMO circuit (DSGC-2021-0179)“ within the project OP VVV" Improvement of the Doctoral Student Grant Competition Schemes and their Pilot Implementation", reg.no. CZ.02.2.69/0.0/0.0/19_073/0016713. Some activities connected with study preparation are created in collaboration with MED MUNI through the CZECRIN project (LM2023049), supported by the national budget through MEYS and from the European Regional Development Fund – project CZECRIN_4 PATIENTS (CZ.02.1.01 / 0.0 / 0.0 / 16_013 / 0001826).

Anotace anglicky

The COL-ECMO2022 study is a prospective, non-randomized, single-center, phase IV clinical trial designed to assess the influence of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics of colistin. Colistin is administered as colistin methanesulfonate (CMS), which is spontaneously hydrolyzed to the active form. Colistin is also a drug with a narrow therapeutic window; the limiting factors are mainly nephrotoxicity and neurotoxicity, both dependent on plasma concentrations. Thirdly, there are limited data on the influence of ECMO on colistin and CMS pharmacokinetics. Up to 30 patients treated with colistin will be included in the study and assigned to one of two arms, depending on the presence/absence of ECMO. All study participants will receive standard CMS dose intravenously. The plasma concentrations of colistin and CMS taken at defined intervals will be assessed by high-performance liquid chromatography-mass spectrometry. Patients will participate in the clinical trial for a maximum of three monitored dosing intervals. A population pharmacokinetic model will be developed to assess the influence of ECMO on pharmacokinetics. The study has been approved by the Ethics Committee of St. Anne's University Hospital Brno (Number 10ML/2022-AM). EudraCT Number of the study is 2022-000291-19, registered on June 21, 2022. The study was registered at the Clinical Trials register https://clinicaltrials.gov/ct2/show/NCT05542446 on September 15, 2022. Acknowledgment: Activities related to the development of a method for the determination of colistin in plasma were covered by a grant Verification of colistin adsorption on the ECMO circuit (DSGC-2021-0179)“ within the project OP VVV" Improvement of the Doctoral Student Grant Competition Schemes and their Pilot Implementation", reg.no. CZ.02.2.69/0.0/0.0/19_073/0016713. Some activities connected with study preparation are created in collaboration with MED MUNI through the CZECRIN project (LM2023049), supported by the national budget through MEYS and from the European Regional Development Fund – project CZECRIN_4 PATIENTS (CZ.02.1.01 / 0.0 / 0.0 / 16_013 / 0001826).

Návaznosti

• LM2023049, projekt VaV: Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Czech National Node to the European Clinical Research Infrastructure Network